BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gonzalez SA, Trotter JF. The rise of the opioid epidemic and hepatitis C-positive organs: A new era in liver transplantation. Hepatology 2018;67:1600-8. [PMID: 29023920 DOI: 10.1002/hep.29572] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Torres HA, Pundhir P, Mallet V. Hepatitis C Virus Infection in Patients With Cancer: Impact on Clinical Trial Enrollment, Selection of Therapy, and Prognosis.Gastroenterology. 2019;157:909-916. [PMID: 30797794 DOI: 10.1053/j.gastro.2019.01.271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
2 Wellington J, Ma A, Kottilil S, Ravichandran B, Husson J, Bruno D, Wilson E. Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis. Viruses 2021;13:1831. [PMID: 34578412 DOI: 10.3390/v13091831] [Reference Citation Analysis]
3 Murag S, Dennis BB, Kim D, Ahmed A, Cholankeril G. Recent advances in liver transplantation with HCV seropositive donors. F1000Res 2019;8:F1000 Faculty Rev-2151. [PMID: 31942236 DOI: 10.12688/f1000research.20387.1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Cron DC, Tincopa MA, Lee JS, Waljee AK, Hammoud A, Brummett CM, Waljee JF, Englesbe MJ, Sonnenday CJ. Prevalence and Patterns of Opioid Use Before and After Liver Transplantation. Transplantation 2021;105:100-7. [PMID: 32022738 DOI: 10.1097/TP.0000000000003155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Wanis KN, Madenci AL, Dokus MK, Tomiyama K, Al-judaibi BM, Hernán MA, Hernandez-alejandro R. The Effect of the Opioid Epidemic on Donation After Circulatory Death Transplantation Outcomes. Transplantation 2019;103:973-9. [DOI: 10.1097/tp.0000000000002467] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Anesi JA, Blumberg EA, Han JH, Lee DH, Clauss H, Climaco A, Hasz R, Molnar E, Alimenti D, West S, Bilker WB, Tolomeo P, Lautenbach E; CDC Prevention Epicenters Program. Risk factors for multidrug-resistant organisms among deceased organ donors. Am J Transplant 2019;19:2468-78. [PMID: 31162785 DOI: 10.1111/ajt.15488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
7 Xue W, Liu K, Qiu K, Shen Y, Pan Z, Hu P, Peng M, Chen M, Ren H. A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation? Int J Infect Dis 2019;83:56-63. [PMID: 30959250 DOI: 10.1016/j.ijid.2019.03.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
8 Kwong AJ, Wall A, Melcher M, Wang U, Ahmed A, Subramanian A, Kwo PY. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am J Transplant. 2019;19:1380-1387. [PMID: 30378723 DOI: 10.1111/ajt.15162] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 16.5] [Reference Citation Analysis]
9 Schulte B, Wübbolding M, Marra F, Port K, Manns MP, Back D, Cornberg M, Stichtenoth DO, Höner Zu Siederdissen C, Maasoumy B. Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. Open Forum Infect Dis 2020;7:ofaa040. [PMID: 32104719 DOI: 10.1093/ofid/ofaa040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Keenan S, Kramer A, Healey A, Weiss MJ, Dhanani S, Beed S, Djogovic D, Sullivan K, Shemie SD. The variable impact of the overdose crisis on organ donation among five Canadian provinces: a retrospective study. Can J Anaesth 2021;68:846-54. [PMID: 33564994 DOI: 10.1007/s12630-021-01945-z] [Reference Citation Analysis]
11 La Hoz RM, Sandıkçı B, Ariyamuthu VK, Tanriover B. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals. Am J Transplant 2019;19:3058-70. [PMID: 31207073 DOI: 10.1111/ajt.15496] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
12 Massoud O. Hepatitis C: looking into the future. Expert Rev Gastroenterol Hepatol 2020;14:367-74. [PMID: 32216467 DOI: 10.1080/17474124.2020.1746641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ohira M, Tanimine N, Kobayashi T, Ohdan H. Essential updates 2018/2019: Liver transplantation. Ann Gastroenterol Surg 2020;4:195-207. [PMID: 32490333 DOI: 10.1002/ags3.12321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Da BL, Ezaz G, Kushner T, Crismale J, Kakked G, Gurakar A, Dieterich D, Schiano TD, Saberi B. Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation. JAMA Netw Open 2020;3:e2027551. [PMID: 33275155 DOI: 10.1001/jamanetworkopen.2020.27551] [Reference Citation Analysis]
15 Kuntzen C, Bagha Z. The Use of Hepatitis C Virus–Positive Organs in Hepatitis C Virus–Negative Recipients. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.012] [Reference Citation Analysis]
16 Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:535-47. [DOI: 10.1016/j.cld.2020.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
17 Cohen S, Cowan V, Rohan V, Pavlakis M, Curry MP, Adler JT, Safa K, Fleishman A, Shenkel J, Rodrigue JR. Willingness of Kidney and Liver Transplant Candidates to Receive HCV-Infected Organs. J Surg Res 2022;278:342-9. [PMID: 35667277 DOI: 10.1016/j.jss.2022.05.003] [Reference Citation Analysis]
18 Sibulesky L, Perkins JD, Landis CS, Johnson CK. Can we mitigate the effects of simultaneous liver-kidney transplantation through increased utilization of HCV-positive donors? Am J Transplant 2018;18:2604-5. [PMID: 30102461 DOI: 10.1111/ajt.15076] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Kreitman KR, Kothadia JP, Nair SP, Maliakkal BJ. Unexpected hepatitis B virus transmission after liver transplant from nucleic acid testing- and serology-negative liver donors who are hepatitis C viremic. Hepatol Res 2021. [PMID: 34114715 DOI: 10.1111/hepr.13680] [Reference Citation Analysis]
20 Bohorquez H, Bugeaud E, Bzowej N, Scheuermann J, Hand J, Bruce D, Carmody I, Cohen A, Joshi S, Seal J, Sonnier D, Therapondos G, Girgrah N, Anders S, Loss GE. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care. Liver Transpl. 2020;. [PMID: 33098277 DOI: 10.1002/lt.25925] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Kapila N, Menon KVN, Al-Khalloufi K, Vanatta JM, Murgas C, Reino D, Ebaid S, Shaw JJ, Agrawal N, Rhazouani S, Navas V, Sheffield C, Rahman AU, Castillo M, Lindenmeyer CC, Miller C, Quintini C, Zervos XB. Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience. Hepatology 2020;72:32-41. [PMID: 31659775 DOI: 10.1002/hep.31011] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 31.0] [Reference Citation Analysis]
22 Crismale JF, Khalid M, Bhansali A, De Boccardo G, Khaim R, Florman SS, Shapiro R, Schiano TD. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study. Clin Transplant 2020;34:e13761. [PMID: 31808193 DOI: 10.1111/ctr.13761] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
23 Forbes RC, Concepcion BP, Clapper D, DuBray BJ, Shawar S, Schaefer HM, Langone A, Shaffer D, Johnson K. The effect of pulsatile pump perfusion on hepatitis C transmission in kidney transplantation: A prospective pilot study. Clin Transplant 2020;34:e13987. [PMID: 32441791 DOI: 10.1111/ctr.13987] [Reference Citation Analysis]
24 Cotter TG, Aronsohn A, Reddy KG, Charlton M. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation 2021;105:1285-90. [DOI: 10.1097/tp.0000000000003382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Predmore Z, Doby B, Bozzi DG, Durand C, Segev D, Sugarman J, Tobian AAR, Wu AW. Barriers experienced by organ procurement organizations in implementing the HOPE act and HIV-positive organ donation. AIDS Care 2021;:1-7. [PMID: 34180726 DOI: 10.1080/09540121.2021.1945999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Yoeli D, Choudhury RA, Nydam TL, Pomposelli JJ, Goss JA, Pomfret EA, Wachs ME, Adams MA. The Surge in Deceased Liver Donors Due to the Opioid Epidemic: Is It Time to Split the Difference? Transplantation 2021;105:2239-44. [PMID: 33065726 DOI: 10.1097/TP.0000000000003491] [Reference Citation Analysis]
27 Kim T, Chhabra N, Weech DM, Leikin JB. Short-Term Graft Failure of Organs Procured from Drug-Related Deaths Compared with Other Causes of Death. J Med Toxicol 2021;17:37-41. [PMID: 32789584 DOI: 10.1007/s13181-020-00801-8] [Reference Citation Analysis]
28 Çiftçibaşı Örmeci A, Yıldız Ç, Saberi B, Gürakar M, Şimşek C, Gürakar A. Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients: The current status and review of literature. Turk J Gastroenterol 2019;30:771-5. [PMID: 31530520 DOI: 10.5152/tjg.2019.18656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Sibulesky L, Limaye AP. Hepatitis C NAT status in the UNOS database. Am J Transplant 2019;19:1870-1870. [DOI: 10.1111/ajt.15303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Schlendorf KH, Zalawadiya S, Shah AS, Perri R, Wigger M, Brinkley DM, Danter MR, Menachem JN, Punnoose LR, Balsara K, Sacks SB, Ooi H, Awad JA, Sandhaus E, Schwartz C, O'Dell H, Carver AB, Edmonds CL, Ruzevich-Scholl S, Lindenfeld J. Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C. JAMA Cardiol 2020;5:167-74. [PMID: 31851352 DOI: 10.1001/jamacardio.2019.4748] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 23.0] [Reference Citation Analysis]
31 Kapila N, Flocco G, Al Khalloufi K, Zervos XB. Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirin. J Viral Hepat 2019;26:407-9. [PMID: 30449062 DOI: 10.1111/jvh.13042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Couri T, Aronsohn A. When Theory Becomes Reality: Navigating the Ethics of Transplanting Hepatitis C Virus-Positive Livers Into Negative Recipients. Clin Liver Dis (Hoboken) 2019;14:131-4. [PMID: 31709040 DOI: 10.1002/cld.849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
33 Nair SP, Marella HK, Maliakkal B, Snyder H, Handley C, Kothadia JP, Ali B, Satapathy SK, Molnar MZ, Clark I, Jain R, Helmick R, Eymard C, Eason JD. Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: Histological and virologic outcome. Clin Transplant 2021;35:e14281. [PMID: 33690929 DOI: 10.1111/ctr.14281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Ariyamuthu VK, Sandikci B, Abdulrahim N, Hwang C, Macconmara MP, Parasuraman R, Atis A, Tanriover B. Trends in utilization of deceased donor kidneys based on hepatitis C virus status and impact of public health service labeling on discard. Transpl Infect Dis 2019;22. [DOI: 10.1111/tid.13204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
35 Nagai S, Chau LC, Schilke RE, Safwan M, Rizzari M, Collins K, Yoshida A, Abouljoud MS, Moonka D. Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease–Sodium Scores on Patient Outcomes. Gastroenterology 2018;155:1451-1462.e3. [DOI: 10.1053/j.gastro.2018.07.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
36 Sobotka LA, Mumtaz K, Wellner MR, Kelly SG, Conteh LF, Hanje AJ, Schenk A, El-Hinnawi A, Black S, Washburn K, Pesavento T, Daloul R, Michaels AJ. Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: A large single center analysis. Ann Hepatol 2021;24:100318. [PMID: 33515801 DOI: 10.1016/j.aohep.2021.100318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Wanis KN, Madenci AL, Dokus MK, Orloff MS, Levstik MA, Hernandez-alejandro R, Hernán MA. The meaning of confounding adjustment in the presence of multiple versions of treatment: an application to organ transplantation. Eur J Epidemiol 2019;34:225-33. [DOI: 10.1007/s10654-019-00484-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Samji H, Yu A, Wong S, Wilton J, Binka M, Alvarez M, Bartlett S, Pearce M, Adu P, Jeong D, Clementi E, Butt Z, Buxton J, Gilbert M, Krajden M, Janjua NZ. Drug-related deaths in a population-level cohort of people living with and without hepatitis C virus in British Columbia, Canada. Int J Drug Policy 2020;86:102989. [PMID: 33091735 DOI: 10.1016/j.drugpo.2020.102989] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Verna EC, Schluger A, Brown RS Jr. Opioid epidemic and liver disease. JHEP Rep 2019;1:240-55. [PMID: 32039374 DOI: 10.1016/j.jhepr.2019.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
40 Chhatwal J, Samur S, Bethea ED, Ayer T, Kanwal F, Hur C, Roberts MS, Terrault N, Chung RT. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Hepatology 2018;67:2085-95. [PMID: 29222916 DOI: 10.1002/hep.29723] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 10.8] [Reference Citation Analysis]
41 Lentine KL, Peipert JD, Alhamad T, Caliskan Y, Concepcion BP, Forbes R, Schnitzler M, Chang SH, Cooper M, Bloom RD, Mannon RB, Axelrod DA. Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers. Kidney360 2020;1:1291-9. [PMID: 33251523 DOI: 10.34067/KID.0004592020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
42 Bethea ED, Samur S, Kanwal F, Ayer T, Hur C, Roberts MS, Terrault N, Chung RT, Chhatwal J. Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. Clin Gastroenterol Hepatol. 2019;17:739-747.e8. [PMID: 30138735 DOI: 10.1016/j.cgh.2018.08.042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
43 Cotter TG, Paul S, Sandıkçı B, Couri T, Bodzin AS, Little EC, Sundaram V, Charlton M. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors. Hepatology 2019;69:2381-95. [PMID: 30706517 DOI: 10.1002/hep.30540] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 11.7] [Reference Citation Analysis]
44 Moayedi Y, Fan CPS, Gulamhusein AF, Manlhiot C, Ross HJ, Teuteberg JJ, Khush KK. Current Use of Hearts From Hepatitis C Viremic Donors: A United Network for Organ Sharing Registry Analysis. Circ: Heart Failure 2018;11. [DOI: 10.1161/circheartfailure.118.005276] [Cited by in Crossref: 22] [Cited by in F6Publishing: 2] [Article Influence: 5.5] [Reference Citation Analysis]
45 Bixler D, Annambholta P, Abara WE, Collier MG, Jones J, Mixson-Hayden T, Basavaraju SV, Ramachandran S, Kamili S, Moorman A. Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017. Am J Transplant. 2019;19:2570-2582. [PMID: 30861300 DOI: 10.1111/ajt.15352] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
46 Wong G, Coates T. To transplant early or treat first? A dilemma for hepatitis C-positive recipients. Kidney Int 2019;96:535-7. [PMID: 31113678 DOI: 10.1016/j.kint.2019.02.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Daniel KE, Said A. Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate. Curr Gastroenterol Rep. 2018;20:20. [PMID: 29623506 DOI: 10.1007/s11894-018-0626-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
48 Italian Association for the Study of the Liver (AISF). AISF position paper on HCV in immunocompromised patients. Dig Liver Dis 2019;51:10-23. [PMID: 30366813 DOI: 10.1016/j.dld.2018.09.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]